RT Journal Article
SR Electronic
T1 Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.21.21266484
DO 10.1101/2021.11.21.21266484
A1 Messiah, Sarah E.
A1 Brito, Frances
A1 Kohl, Harold W.
A1 DeSantis, Stacia
A1 Valerio-Shewmaker, Melissa
A1 Ross, Jessica
A1 Swartz, Michael D.
A1 Yaseen, Ashraf
A1 Kelder, Steven H.
A1 Zhang, Shiming
A1 Omega-Njemnobi, Onyinye S
A1 Gonzalez, Michael O.
A1 Wu, Leqing
A1 Boerwinkle, Eric
A1 Lakey, David
A1 Shuford, Jennifer A.
A1 Pont, Stephen J.
YR 2021
UL http://medrxiv.org/content/early/2021/11/24/2021.11.21.21266484.abstract
AB Background Recent data suggest the SARS-CoV-2 Delta (B.1.617.2) variant is more transmissible among children compared to the Alpha (B.1.1.7) variant. The true incidence and longitudinal presence of antibody response to SARS-CoV-2 infection is not known, however. We provided estimates of antibody response using Texas Coronavirus Antibody REsponse Survey (Texas CARES) data, a prospective population-based seroprevalence project designed to assess antibody status over time among the general population throughout the state.Methods In October 2020 Texas CARES began enrolling adults (aged 20-80 years) and children (aged 5-19 years). Participants were offered a series of three SARS-CoV-2 antibody tests over 6-8 months, or every 2-3 months that includes the immunoassay for detection of antibodies to the SARS-CoV-2 nucleocapsid protein (Roche N-test). Descriptive characteristics and COVID-19 infection-related symptom status was determined by questionnaire at the time of enrollment and prior to each successive blood draw. This analysis included participants ages 5-to-19 years old who have completed all three antibody assessments.Results From our sample (n=159; mean age 12.5 years, SD 3.6), 96% of those with evidence of nucleocapsid antibodies at baseline assessment continued to have antibodies > six months later (mean 7.0 months, SD 0.97). There was no difference in the presence of antibodies by symptom status (asymptotic versus symptomatic) or severity (mild-moderate versus severe), sex, age group, or body mass index group (underweight, healthy weight, overweight, obesity) over the three antibody measurement timepoints.Conclusions These results suggest that infection-induced antibodies persist and thus may provide some protection against future infection for at least half a year. 57.9% of the sample were negative for infection-induced antibodies at their third measurement point, suggesting a significant proportion of children have still not acquired natural infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Texas Department of State Health Services (Contract #HHS000866600001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All protocols were reviewed and approved by the University of Texas Health Science Center, Committee for the Protection of Human Subjects, but also deemed public health practice by the Texas Department of State Health Services IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTexas CARES investigators are committed to data sharing. Granular results and user-specified data summaries are currently publicly available on the Texas CARES portal (https://sph.uth.edu/projects/texascares/dashboard). When baseline recruitment is complete, a deidentified individual level dataset will be available for download from the same portal. https://sph.uth.edu/projects/texascares/dashboard COVID-19coronavirus disease 2019DSHSDepartment of State Health ServicesSARS-CoV-2severe acute respiratory syndrome coronavirus 2Texas CARESTexas COVID-19 Antibody Response Survey